FIELD: medicine.
SUBSTANCE: invention refers to medicine, particularly to applying a neutralising antibody to matrix metalloproteinase-10 (MMP-10) for preparing a drug applicable for antifibrinolytic therapy and treating bleedings and hemorrhagic complications of various aetiology: hyperfibrinolytic conditions caused by congenital pathologies, anticoagulant therapy, surgical procedures.
EFFECT: invention provides higher selectivity of inhibitors which block molecular mechanisms associated with specific matrix metalloproteinases that allows avoiding undesired events.
7 cl, 4 ex, 2 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| USING MATRIC METALLOPROTEINASE-10 (MMP-10) FOR THROMBOLYTIC THERAPY | 2008 |
|
RU2489163C2 |
| HYPERFIBRINOLYSIS PREDICTION AND DIAGNOSTIC TECHNIQUE | 2007 |
|
RU2358657C2 |
| PHARMACEUTICAL COMPOSITION COMPRISING FACTOR VIIA AND FACTOR XIII | 2001 |
|
RU2272648C2 |
| PHARMACEUTICAL COMPOSITION POSSESSING FIBRINOLYTIC EFFECT | 2007 |
|
RU2323001C1 |
| COMBINATION THERAPY FOR TREATING HEMORRHAGIC SHOCK | 2018 |
|
RU2663464C1 |
| COMBINATION THERAPY FOR TREATING HEMORRHAGIC SHOCK | 2015 |
|
RU2651778C2 |
| METHOD OF TREATMENT OF CHRONIC PROSTATITIS | 0 |
|
SU1281271A1 |
| METHOD FOR PREVENTING COMPLICATIONS IN PERFORMING CAVITARY SURGICAL OPERATIONS ON EYES | 1994 |
|
RU2115398C1 |
| METHOD OF INHIBITING THROMBUS FORMATION AND ACCELERATION OF FIBRINOLYSIS WITH DNA APTAMERS INHIBITING ACTIVITY OF THROMBIN IN EXPERIMENT | 2014 |
|
RU2559545C1 |
| PHARMACEUTICAL COMPOSITION ELICITING THROMBOLYTIC AND FIBRINOLYTIC EFFECT | 2002 |
|
RU2216348C1 |
